Help 4 HD News Update with First HD

PRE-RECORDED   - First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months. Tonight listen to our special guests Dr. Samuel Frank - Associate Professor of Neurology and co-Director of Neurology Resident Education at Boston University and is involved with many HSG studies and trials, and David Stamler - Chief Medical Officer at Auspex Pharmaceuticals.  Help 4 HD International Inc. is thrilled to be working with Auspex and HSG as their premiere communications partner.